Many analysts and doctors believe Arcoxia will only be approved after that study is completed and it demonstrates the drug doesn't increase the risk of heart attacks and strokes The 7,111-patient trial that was presented Tuesday at the American College of Rheumatology's annual meeting in San Antonio, and is part of the Merck's application for approval.
Now there are concerns that the entire class of drugs cause similar problems The European Medicines Agency said its review will look at all aspects of cardiovascular safety of the Cox-2 drugs.
Most analysts and doctors were expecting the FDA to seek additional information
